OS Therapies targets mid-Q4 2026 start for UK Phase 3 OST-HER2 trial in metastatic osteosarcoma
Bitget2026/09/21 10:31- OS Therapies outlined plans to seek early market access for OST-HER2 in metastatic osteosarcoma via a U.K. conditional filing in coming weeks.
- MHRA is set to lead the Project Orbis review, positioning the program for coordinated decisions across major regulators.
- FDA alignment on an amended Phase 3 design supports a confirmatory trial start in the U.K. in mid-Q4 2026.
- Access to the U.K. national patient registry is expected to strengthen comparator evidence while the Phase 3 study runs.
- No new clinical results were presented; the update focused on trial timing and the regulatory pathway toward potential early launch.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canton Network breaks 2 month range! – CC’s run to $0.15 depends on THIS zone
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
Crypto prices
More
